Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.

Elashoff, Michael; Matveyenko, Aleksey V; Gier, Belinda; Elashoff, Robert; Butler, Peter C
Gastroenterology; 2011 Jul;141(1):150-6. PMID: 21334333
Larry L. Hillblom Islet Research Center at David Geffen School of Medicine and Department of Biomathematics, University of California, Los Angeles, California 90095-7073, USA.


Glucagon-like peptide-1-based therapy is gaining widespread use for type 2 diabetes, although there are concerns about risks for pancreatitis and pancreatic and thyroid cancers. There are also concerns that dipeptidyl peptidase-4 inhibitors could cause cancer, given their effects on immune function.